2018-08-06

[#DIV28SUPER] Important Funding Opportunities you should know about, NIDA Neuroscience Update August 6, 2018

 

I.         PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed)

Application due dates: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, by 5:00 PM local time of applicant organization.

 

II.        PAR-18-226  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)   Application deadline: October 19, 2018, by 5:00 PM local time of applicant organization

 

III.      PAR-18-084: Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) Standard receipt dates, FOA expires Sept 8, 2019 (not 2018)

 

IV.      PAR-17-242/PAR-17-250 Extracellular Vesicles and Substance Use Disorders (R21) and R01)

Application deadline: November 3, 2018, March 3, 2019, November 3, 2019, March 3, 2020 , by 5:00 PM local time of applicant organization.

 

V.       PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)  Application deadline: November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization

 

VI.      Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

Application deadline: August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020, by 5:00 PM local time of applicant organization.

 

VII.    Call for Presentations by funded NIDA and NIAAA Early Stage and New Investigators to present at the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention on Friday, November 2, in San Diego, CA, Satellite to Society for Neuroscience Meeting. Please complete the ECIS application form

VIII.    Hold the date for the NIDA Genetics Consortium Meeting, Monday, January 14 through January 15, 2019.  

 

------------------------

 

I.           PAR-18-789 Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed)  Application due dates: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, by 5:00 PM local time of applicant organization.

 

The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants.

Investigators examining the phenotype of knockout mice are discouraged from submitting applications to this FOA. Instead, they should submit applications in response PA-17-155 (R01) PA-17-157 (R21) Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders.”

 

II.     PAR-18-226  Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)   Application deadline: October 19, 2018, by 5:00 PM local time of applicant organization

 

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.  These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction.  Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply.  The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

III.   PAR-18-084: Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) Standard receipt dates, FOA expires Sept 8, 2019 (not 2018)

 

The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

 

IV.     PAR-17-242/PAR-17-250 Extracellular Vesicles and Substance Use Disorders (R21) and R01)  Application deadline: November 3, 2018, March 3, 2019, November 3, 2019, March 3, 2020 , by 5:00 PM local time of applicant organization.

 

The purpose of this FOA is to encourage research projects that investigate the interplay between EVs and SUDs.  In particular, NIDA is interested in the potential utility of EVs with respect to understanding neuroplastic mechanisms relevant to SUDs or as biomarkers or therapeutics.

 

Proposed projects are expected to meet the following two criteria: 1) the major thrust of the application should involve extracellular vesicles or EV biogenesis machinery; and 2) at least one aim or sub-aim should involve exposure to addictive substances, or analysis of samples from patients with substance use or SUDs. Addictive substances of interest include: nicotine, cocaine, stimulants, opioids, prescription drugs, cannabinoids, or use of multiple substances (including alcohol).  Applications focused solely on alcohol exposure should not apply through this FOA. 

 

V.    PAR-18-742 Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)  Application deadline: November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization

 

The purpose of this initiative is to encourage research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain.  Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response

 

VI     Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

Application deadline: August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020, by 5:00 PM local time of applicant organization.

 

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research. 

 

 

VII.         Call for Presentations by funded NIDA and NIAAA Early Stage and New Investigators to present at the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention on Friday, November 2, in San Diego, CA, Satellite to Society for Neuroscience Meeting.

This year’s scientific sessions for the 2018 Mini-Convention will explore: 1) data science – new paradigms for addiction research; 2) effects of early life adversity on substance use disorder-related circuitry; and 3) novel opioid receptor signaling in addiction and pain.

Funded NIDA and NIAAA Early Stage ESI and New Investigators are urge to submit papers for oral presentation at the Early Career Investigator Showcase [ECIS] session of the 2018 NIDA-NIAAA Frontiers in Addiction Research Mini-Convention. Investigators whose papers are selected for presentation at the ECIS will be provided with a travel award to attend the meeting. Individuals selected for ECIS will be chosen for the quality of their research, its impact in the field, and its relevance to the mission of NIDA or NIAAA. Preference will be given to presentations that address a scientific session of the 2018 Mini-Convention. 

Please complete the ECIS application form contained in this hyperlink.   Applications are due by 17 August 2018. Please send your application by email to: Roger Sorensen, NIDA [rsorense@mail.nih.gov ] or John Matochik, NIAAA [jmatochi@mail.nih.gov ].

VIII.         Hold the date for the NIDA Genetics Consortium Meeting, Monday, January 14 through January 15, 2019

 

The NIDA Genetics Consortium meeting is where the latest information and data about the of science of genetics and epigenetics of substance abuse is presented.  A call for posters presentation will occur in late September -early October, 2018.  For more information contact

Jonathan D. Pollock,Ph.D. (jpollock@mail.nih.gov, 301-435-1309) or Amy Lossie, Ph.D. (amy.lossie@nih.gov 301-827-6069)

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

No comments:

Post a Comment